LRRC8A and lung cancer: Thorsteinsdottir et al. conducted a study in which it was observed that protolichesterinic acid, in addition to reducing human lung cancer cells’ (A549) viability, also induced a decrease in Leucine Rich Repeat Containing 8 VRAC Subunit A (LRRC8A) protein expression, as well as volume-sensitive taurine release under hypotonic conditions [126].